Friday, October 21, 2022, 8:30 AM – Saturday, October 22, 2022, 6:30 PM, Arthur H. Rubenstein Auditorium, Smilow Center for Translational Research and On-Line (Hybrid), Philadelphia, PA

Penn Medicine State of Art Heart Failure Course 2022

This course will provide a comprehensive, state of the art update on the management of heart failure focusing on the recently updated ACC/AHA Heart Failure Management Guidelines. The course is divided into six threads each focusing on a unique aspect of heart failure management from medical and device therapies, recognition of unique etiologies of heart failure, management of cardiogenic shock and selection for advanced therapies including transplant and ventricular assist devices. Each thread will have one or more cases to illustrate diagnostic and therapeutic challenges followed by panel discussions and audience participation to make the material actionable in daily practice.

Two keynote speakers, one each day, will provide a visionary overview of the days’ topics and provide valuable perspective from a thought leader. A unique aspect of this course will be a mock patient selection committee meeting for heart transplant and ventricular assist device to include a representative of each of the disciplines present during these life and death deliberations.

This will be an opportunity to see, first hand, how patients are presented and which clinical and psychosocial aspects are considered in advanced therapy patient selection. The program includes a debate as well as a presentation from a patient who had a ventricular assist device and went on to have a heart transplant. The faculty will include heart failure cardiologists, interventional cardiologists, cardiothoracic surgeons, electrophysiologists, advanced practice providers, social workers, a patient and other members of the Heart Team.

1. Describe evidence based therapies for the treatment of heart failure including SGLT-2 inhibitors and soluable guanylate cyclase activators
2. Explain how to increase the percent of patients with heart failure with reduced ejection fraction receiving all 4 guideline directed classes of medications
3. Describe evidence based therapies for hypertrophic cardiomyopathy and amyloid cardiomyopathy
4. Explain the indications for TAVR and mitral valve edge to edge repairs
5. Explain the indications for remote monitoring of heart failure patients
6. Formulate appropriate approaches to overcoming barriers to achieving heart failure guideline directed medical and device therapies
7. Identify patients who may benefit from cardiac contractility management, biventricular pacing and ICD’s
8. Describe patient characteristics that are associated with improved outcomes following revascularization procedures
9. Identify evidence based therapies for heart failure with preserved ejection fraction
10. Describe the impact of COVID-19 on the heart
11. Explain the mechanisms of action and cardiac risks of cancer chemotherapeutic agents
12. Identify clinical, laboratory, imaging and psychosocial factors that predict outcome in heart transplant and ventricular assist devices
13. Describe the use of genetic testing in identifying genetic causes of cardiomyopathy
14. Identify when to refer a patient to a multidisciplinary heart failure program
15. Describe the roles and responsibilities of members of the interprofessional heart failure team